GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MetaStat Inc (OTCPK:MTST) » Definitions » Operating Income

MetaStat (MetaStat) Operating Income : $-3.55 Mil (TTM As of Feb. 2018)


View and export this data going back to 2008. Start your Free Trial

What is MetaStat Operating Income?

MetaStat's Operating Income for the three months ended in Feb. 2018 was $-0.88 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Feb. 2018 was $-3.55 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. MetaStat's Operating Income for the three months ended in Feb. 2018 was $-0.88 Mil. MetaStat's Revenue for the three months ended in Feb. 2018 was $0.00 Mil. Therefore, MetaStat's Operating Margin % for the quarter that ended in Feb. 2018 was %.

MetaStat's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. MetaStat's annualized ROC % for the quarter that ended in Feb. 2018 was -246.98%. MetaStat's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2018 was -1,030.92%.


MetaStat Operating Income Historical Data

The historical data trend for MetaStat's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MetaStat Operating Income Chart

MetaStat Annual Data
Trend Feb09 Feb10 Feb11 Feb12 Feb13 Feb14 Feb15 Feb16 Feb17 Feb18
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.35 -4.79 -4.78 -3.35 -3.55

MetaStat Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.83 -0.74 -0.78 -1.15 -0.88

MetaStat Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Feb. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MetaStat  (OTCPK:MTST) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

MetaStat's annualized ROC % for the quarter that ended in Feb. 2018 is calculated as:

ROC % (Q: Feb. 2018 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Nov. 2017 ) + Invested Capital (Q: Feb. 2018 ))/ count )
=-3.512 * ( 1 - 0% )/( (1.446 + 1.398)/ 2 )
=-3.512/1.422
=-246.98 %

where

Note: The Operating Income data used here is four times the quarterly (Feb. 2018) data.

2. Joel Greenblatt's definition of Return on Capital:

MetaStat's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2018 is calculated as:

ROC (Joel Greenblatt) %(Q: Feb. 2018 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Nov. 2017  Q: Feb. 2018
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-3.768/( ( (0.377 + max(-0.833, 0)) + (0.354 + max(-1.065, 0)) )/ 2 )
=-3.768/( ( 0.377 + 0.354 )/ 2 )
=-3.768/0.3655
=-1,030.92 %

where Working Capital is:

Working Capital(Q: Nov. 2017 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.071) - (0.879 + 0.025 + 0)
=-0.833

Working Capital(Q: Feb. 2018 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.015) - (1.08 + 0 + 0)
=-1.065

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Feb. 2018) EBIT data.

3. Operating Income is also linked to Operating Margin %:

MetaStat's Operating Margin % for the quarter that ended in Feb. 2018 is calculated as:

Operating Margin %=Operating Income (Q: Feb. 2018 )/Revenue (Q: Feb. 2018 )
=-0.878/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


MetaStat Operating Income Related Terms

Thank you for viewing the detailed overview of MetaStat's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


MetaStat (MetaStat) Business Description

Traded in Other Exchanges
N/A
Address
27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210
MetaStat Inc is a US-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.
Executives
Daniel H Schneiderman officer: VP OF FINANCE AND SECRETARY 760 PARKSIDE AVE. SUITE 304, SUITE 207, BROOKLYN NY 11226
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Paul Billings director 11055 FLINTKOTE AVENUE, SUITE B, SAN DIEGO CA 92121
Richard J Berman director 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Martin J Driscoll director C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Oscar Bronsther director 4 AUTUMNWOOD COURT, THE WOODLANDS TX 77380
Johan M. Spoor director 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
David N Siegel director T-S CAPITAL PARTNERS, LLC, 1350 TREAT BOULEVARD, SUITE 400, WALNUT CREEK CA 94597
Warren C Lau director 2635 N. CRESCENT RIDGE DRIVE, THE WOODLANDS TX 77381
Patrick T Mooney director C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
David M. Epstein director OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD, MELVILLE NY 11747
Richard W Perkins 10 percent owner 730 EAST LAKE STREET, WAYZATA MN 55391
Harvey Judkowitz director 10220 SW 124 ST, MIAMI FL 33176

MetaStat (MetaStat) Headlines

No Headlines